Photo Credit: Muhammad Shoaib
The following is a summary of “SARS-CoV-2 seroprevalence among people living with HIV in the German HIV-1 Seroconverter Cohort, 2020–2022,” published in the November 2024 issue of Infectious Disease by Hohn et al.
Researchers conducted a retrospective study to analyze the dynamic rise of SARS-CoV-2 seroprevalence in People living with HIV (PLWH) in Germany during the first 3 years of the pandemic, comparing it to the general population.
They analyzed blood samples (N=93/month) from the German HIV-1 Seroconverter Cohort in PLWH with well-defined seroconversion dates. Blood samples from 1,569 PLWH were tested for the presence of anti-S1 antibodies and, if positive, also for anti-N antibodies.
The results showed that anti-S1 positivity increased from 0-6.9% in 2020 to 35% in May 2021, with 3.2% also anti-N positive. In 2022, the average anti-S1 seroprevalence was 97.5% and anti-N positivity was associated with younger age, and females were overrepresented among anti-S1/anti-N negative samples.
They concluded that the anti-S1 seroprevalence in PLWH in 2020 was comparable to the general population but increased earlier in 2021 due to vaccination prioritization and infections during the third wave.
Source: bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-10119-3
